



MEDICAL DEVELOPMENTS INTERNATIONAL LIMITED

ABN 14 106 340 667

FACTORY 7, 56 SMITH ROAD, SPRINGVALE, VICTORIA 3171, AUSTRALIA

Telephone: +61 3 9547 1888 Facsimile: +61 3 9547 0262

Web: www.medicaldev.com Email: mdi@medicaldev.com

ASX RELEASE

Successful Inspection increases confidence of Registration in Gulf States by September

MVP today announced that an Inspection Team from the GCC countries (Saudi Arabia, Kuwait, UAE, Bahrain, Oman and Qatar) had completed its inspection of MVP's facilities in Springvale, Victoria and is on track to achieve final product registration by September 2005.

Registration Process in GCC countries

To market Pentrox™ in the GCC, MVP is required to complete a two step registration process. The first (and most lengthy) process is the approval of MVP as a Manufacturer of Pentrox™. This process culminates in the issue of a Manufacturing Licence. The second step, which can only begin after the Manufacturing Licence has been approved, is the approval of our product, Pentrox™.

MVP applied for a Manufacturing Licence in September 2004. An Inspection Team from the GCC, comprising representatives from the Ministries of Health of Saudi Arabia, Bahrain and Kuwait, completed an audit of MVP's manufacturing plant on Thursday 7 April, 2005. This team has advised they will recommend to their Committee that MVP be issued with a Manufacturing Licence. The GCC Committee is due to meet at the end of April and it is expected that the Committee will approve the issue of a Manufacturing Licence to MVP. It may take several weeks from this approval for the Manufacturing Licence to issue.

MVP will file the application for Product Approval immediately the Manufacturing Licence is issued. The GCC Inspection Team advised that this process typically takes 3-4 months which should result in a final Product Approval by September 2005.

The GCC Market

The GCC countries have a combined population in excess of 35 million people; approximately double the population of Australia. They are affluent countries with well funded health sectors. Market interest in Pentrox™ has been high as evidenced by pre-registration sales to the Ambulance Service operated by Dubai Police.

Further Information:

Mr Chris Weaver
Chief Executive Officer
03 9547 1888

Mr David Williams
Chairman
0414 383 593